- Home
- FGI vs APLM Comparison
FGI vs APLM Comparison
Compare FGI & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGI
- APLM
- Stock Information
- Founded
- FGI 1987
- APLM 2016
- Country
- FGI United States
- APLM United States
- Employees
- FGI N/A
- APLM N/A
- Industry
- FGI Industrial Specialties
- APLM Blank Checks
- Sector
- FGI Industrials
- APLM Finance
- Exchange
- FGI Nasdaq
- APLM Nasdaq
- Market Cap
- FGI 6.8M
- APLM 6.1M
- IPO Year
- FGI 2022
- APLM N/A
- Fundamental
- Price
- FGI $3.63
- APLM $5.67
- Analyst Decision
- FGI
- APLM
- Analyst Count
- FGI 0
- APLM 0
- Target Price
- FGI N/A
- APLM N/A
- AVG Volume (30 Days)
- FGI 59.1K
- APLM 50.0K
- Earning Date
- FGI 08-11-2025
- APLM 08-26-2025
- Dividend Yield
- FGI N/A
- APLM N/A
- EPS Growth
- FGI N/A
- APLM N/A
- EPS
- FGI N/A
- APLM N/A
- Revenue
- FGI $135,904,413.00
- APLM $198,000.00
- Revenue This Year
- FGI $7.72
- APLM $415.15
- Revenue Next Year
- FGI $6.94
- APLM N/A
- P/E Ratio
- FGI N/A
- APLM N/A
- Revenue Growth
- FGI 12.30
- APLM N/A
- 52 Week Low
- FGI $2.28
- APLM $4.47
- 52 Week High
- FGI $5.50
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- FGI 47.51
- APLM 45.08
- Support Level
- FGI $3.26
- APLM $5.50
- Resistance Level
- FGI $3.87
- APLM $6.28
- Average True Range (ATR)
- FGI 0.56
- APLM 0.41
- MACD
- FGI -0.07
- APLM 0.00
- Stochastic Oscillator
- FGI 22.70
- APLM 20.80
About FGI FGI Industries Ltd.
FGI Industries Ltd is a supplier of kitchen and bath products. The company is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. The company offers products that fall into four categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The company generates the majority of its revenue from the sale of Sanitaryware products. Geographically, the company generates the majority of its revenue from the United States, followed by Canada and Europe.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.